NEWS

December 10, 2019

BOULDER, Colo.--(BUSINESS WIRE)--Inscripta, Inc., today announced the company has raised $125 million in a Series D financing with support from the company’s existing investors and new investors JS Capital Management LLC and Oak HC/FT. Paladin Capital Group led the round, bringing the total amount raised by the company to $259.5 million. The new funds will be used to accelerate applications expansion and commercialization of the company’s revolutionary Onyx™ Digital Genome Engineering platform.

Serial Biotech Entrepreneur Kevin Ness Has Raised $260 Million To Get His Genome-Engineering Device Into The Hands Of Every Scientist Who Wants One

December 05, 2019

The Rabobank Award for Emerging Leadership in Innovation is given to a fast-growing young company that is addressing challenges and market gaps in F&A with a novel and disruptive business model. The 2019 award is presented to Berkeley, California-based Pivot Bio, a company that provides a microbial nitrogen crop nutrition solution to farmers that reduces the use of synthetic nitrogen fertilizers, helping farmers improve their profitability and sustainability. Pivot Bio was recognized as one of the Most Innovative AgTech Startups of 2018 by Forbes and one of the World’s Most Innovative Companies in 2019 by Fast Company. 

October 01, 2019

The Onyx™ platform enables scientists to create libraries of millions of precisely engineered single cells in one experiment through a fully automated workflow.

Inscripta, Inc., today announced the launch of the Onyx™ Digital Genome Engineering platform, the world’s first fully automated benchtop instrument for genome-scale engineering. The CRISPR-mediated, massively parallel platform — which includes software, consumables, instrument, and assays — enables researchers to engineer microbial libraries containing the full breadth and scope of possible edit types, in their own labs. This new genome engineering platform will offer immediate and significant benefits that will support bio-industrial materials development and manufacturing, genome discovery, healthcare, and sustainability. 

hat makes it interesting? Write a catchy description to grab your audience's attention...

October 15, 2019

SANTA MONICA, Calif., Oct. 15, 2019 /PRNewswire/ -- Provivi, Inc., an emerging crop protection company, today announced it has completed an $85 million Series C financing. The round was co-led by Pontifax Global Food and Agriculture Fund ("Pontifax Agtech") and a global investment fund. The round also included new investor Tybourne Capital Management. Existing investors Kairos Ventures, Spruce Capital, Lanx Capital, and BASF Venture Capital also participated in the round.

"The Series C financing is a significant milestone in the growth of our company and builds upon an exciting year where we scaled the production of key pheromone active ingredients, continued to demonstrate the efficacy of our products in row crops, and worked closely with farmers to demonstrate the value being created by our pheromones in field trials," said Dr. Pedro Coelho, co-founder and CEO of Provivi. "The extraordinary conditions facing growers all over the world caused by invasive pests renews our sense of urgency to scale our solutions."

Additional coverage:  AgFunder

April 04, 2019

NEW YORK (GenomeWeb) – Gene editing technology company Inscripta said today that it that its existing investors have agreed to contribute an additional $20 million to its previously announced Series C funding round, bringing the total raised in the round to $105.5 million.

In February 2018, the company said it had raised $55.5 million from Venrock, Foresite, Mérieux Développement, Paladin Capital Group, MLS Capital, and NanoDimension. In December, the same investors contributed an additional $30 million to the round, bringing the total to $85.5 million. The same investors have now contributed the additional $20 million, Inscripta said.

March 26, 2019

I’ve written about them several times over the last six months, and I bring them up in polite conversation more than I should. In my defense, I have a legitimate reason: cows, with their burps and farts, are a good example of something that contributes to climate change but isn’t related to generating electricity...

December 19, 2018

Existing investors contribute an additional $30 million to accelerate tools that will revolutionize genomic research

Boulder, CO – December 19, 2018 – Inscripta™, a leading gene-editing technology company, today announced that MAD7, its proprietary CRISPR enzyme, has achieved wide adoption by academic, commercial, and government researchers in its first year of availability. MAD7 was recently recognized by the Scientist magazine as one of the “Top 10 Innovations of 2018."

January 22, 2019

Cavallo Ventures, the venture capital arm of Wilbur-Ellis, has invested in Crop Enhancement Inc., an innovator of sustainable agrochemical products for enhancing crop yields. With its investment, Cavallo Ventures aims to accelerate the development of Crop Enhancement's breakthrough crop protection technology in the United States — particularly for the production of high-value fruit and vegetable crops.

Cavallo Ventures Makes Seven Figure Investment In Pesticide Disruption

November 27, 2018

Santa Monica, California, November 27, 2018 – Provivi™, an emerging company using pheromones to protect crops from major damaging insects, today announced a $5 million expansion to a $31.5 million Series B, bringing the round total to $36.5 million.

The expansion featured participation from both existing and new investors. BASF Venture Capital and Corteva Agriscience™, Agriculture Division of DowDuPont, also participated in the expanded round as strategic investors.

October 03, 2018

Nitrogen-fixing bacteria may not sound like the most alluring topic, but it's capturing the attention of the world's most influential billionaires, who see it as a concrete way to help save the planet...In its latest round of funding, California-based startup Pivot Bio raised $70 million for its genetically modified bacteria, with the majority of funds coming from BEV...

1 / 7

Please reload